Meeting
2014 ASCO Annual Meeting
A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC).
Authors
David Paul Carbone
Ohio State University Wexner Medical Center, Columbus, OH
David Paul Carbone , Mark A. Socinski , Allen C. Chen , Prabhu Bhagavatheeswaran , Martin Reck , Luis Paz-Ares
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02041533
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS8128)
DOI
10.1200/jco.2014.32.15_suppl.tps8128
Abstract #
TPS8128
Poster Bd #
304A
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.
First Author: Martin Reck
Poster
2018 ASCO Annual Meeting
Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.
First Author: Nathaniel R. Evans
Poster
2017 ASCO Annual Meeting
IMpower132: A phase III clinical program—1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC.
First Author: Howard Jack West
Poster
2024 ASCO Annual Meeting
eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%.
First Author: Melissa Lynne Johnson